Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference
Pulse Biosciences (Nasdaq: PLSE), a pioneer in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its participation in the 24th Annual Needham Virtual Health Care Conference. The company's management team is scheduled to deliver a presentation on Thursday, April 10, 2025, at 9:30 am ET.
Investors and interested parties can access both the live and recorded versions of the presentation through the company's investor relations website at investors.pulsebiosciences.com, specifically on the 'Events Calendar and Presentations' page.
Pulse Biosciences (Nasdaq: PLSE), un pioniere nella tecnologia di Ablazione a Campo Pulsato in Nanosecondi™ (nsPFA™), ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale sulla Salute di Needham. Il team di gestione dell'azienda è programmato per presentare il proprio intervento giovedì 10 aprile 2025, alle 9:30 ET.
Gli investitori e le parti interessate possono accedere sia alla versione dal vivo che a quella registrata della presentazione attraverso il sito web delle relazioni con gli investitori dell'azienda all'indirizzo investors.pulsebiosciences.com, specificamente nella pagina 'Calendario Eventi e Presentazioni'.
Pulse Biosciences (Nasdaq: PLSE), un pionero en la tecnología de Ablación por Campo Pulsado en Nanosegundos™ (nsPFA™), ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham. El equipo de gestión de la empresa tiene programada una presentación el jueves 10 de abril de 2025, a las 9:30 am ET.
Los inversores y partes interesadas pueden acceder tanto a la versión en vivo como a la grabada de la presentación a través del sitio web de relaciones con inversores de la empresa en investors.pulsebiosciences.com, específicamente en la página 'Calendario de Eventos y Presentaciones'.
Pulse Biosciences (Nasdaq: PLSE)는 나노초 펄스 필드 절제™ (nsPFA™) 기술의 선두주자로, 제24회 니드햄 연례 가상 건강 관리 회의에 참여한다고 발표했습니다. 회사의 경영진은 2025년 4월 10일 목요일, 오전 9시 30분 ET에 발표를 진행할 예정입니다.
투자자와 관심 있는 분들은 회사의 투자자 관계 웹사이트인 investors.pulsebiosciences.com을 통해 발표의 실시간 및 녹화된 버전을 모두 이용할 수 있으며, 특히 '이벤트 일정 및 발표' 페이지에서 확인할 수 있습니다.
Pulse Biosciences (Nasdaq: PLSE), un pionnier dans la technologie de l'Ablation par Champ Pulsé en Nanosecondes™ (nsPFA™), a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Santé de Needham. L'équipe de direction de l'entreprise doit présenter le jeudi 10 avril 2025, à 9h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à la version en direct ainsi qu'à la version enregistrée de la présentation via le site web des relations investisseurs de l'entreprise à l'adresse investors.pulsebiosciences.com, spécifiquement sur la page 'Calendrier des Événements et Présentations'.
Pulse Biosciences (Nasdaq: PLSE), ein Pionier in der Nanosekunden-Pulsfeld-Ablation™ (nsPFA™)-Technologie, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben. Das Management-Team des Unternehmens wird voraussichtlich am Donnerstag, den 10. April 2025, um 9:30 Uhr ET eine Präsentation halten.
Investoren und Interessierte können sowohl die Live- als auch die aufgezeichnete Version der Präsentation über die Investor-Relations-Website des Unternehmens unter investors.pulsebiosciences.com, insbesondere auf der Seite 'Veranstaltungskalender und Präsentationen', abrufen.
- None.
- None.
Pulse Biosciences’ Management is scheduled to present on Thursday, April 10, 2025, at 9:30 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the company’s investor website at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326173688/en/
Investors:
Pulse Biosciences, Inc.
Jon Skinner, CFO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
When is Pulse Biosciences (PLSE) presenting at the Needham Healthcare Conference 2025?
How can investors watch PLSE's Needham Conference presentation?
What is the main technology focus of Pulse Biosciences (PLSE)?
Which major healthcare conference will PLSE attend in April 2025?
